Study
Tau-induced mitochondrial reverse electron transport drives neurodegeneration
Hyperphosphorylated tau entered mitochondria, triggered reverse electron transport, and created a self-reinforcing oxidative-stress loop.
Summary Could harmful tau damage mitochondria in a way that worsens brain disease? Show / hide ↓
Researchers studied fruit flies, mice, donated human brain tissue, and lab-grown human nerve cells made from stem cells. They found that stressed tau, a brain protein with extra phosphate groups attached, entered mitochondria, the cell’s energy factories, and attached to a part of them called NDUFS3. This triggered reverse electron transport, an abnormal backward flow of energy-related electrons that creates reactive oxygen species, unstable molecules that can damage cells. The damage lowered the NAD+/NADH ratio, a measure of the cell’s chemical energy balance, and caused more tau changes, creating a harmful loop. Removing tau or using the experimental compound CPT reduced damage in the animal and cell models, but CPT has not been tested in people.
What this means for you: This is an interesting early target for future drug development, not a treatment you can use now. It does not show that NAD supplements help tau-related diseases, and there is no reason to buy CPT products.
early evidenceLi and colleagues describe a mitochondrial mechanism linking tau pathology to neuronal damage. In flies, mice, human brain tissue, and human iPSC-derived neurons, tau entered mitochondria under stress when phosphorylated. It bound the complex I subunit NDUFS3 and promoted mitochondrial reverse electron transport. The process increased reactive oxygen species, lowered the NAD+/NADH ratio, and further promoted tau hyperphosphorylation. Tau depletion eliminated stress-induced reverse electron transport and improved resilience. In tauopathy models, the experimental compound CPT blocked the tau-NDUFS3 interaction. CPT reduced neuroinflammation and neurodegeneration, improved behavioral performance, and extended lifespan in stressed flies. The same direction of effect appeared in human neuronal models carrying pathogenic tau mutations. This is a strong mechanistic paper with cross-species validation. It is not a human treatment trial. CPT is an experimental compound and has not entered clinical testing. The NAD+/NADH result is mechanistic, not evidence that oral NAD precursors treat tauopathies. The paper matters for longevity biology because it identifies a stress-sensitive mitochondrial loop that may become more damaging with age. The immediate implication is a target for drug development, not a supplement recommendation.
RET regulation thus represents a previously unrecognized normal function of tau that becomes pathological in disease, providing a therapeutic target for various conditions characterized by tau abnormalities and mitochondrial dysfunction.
The intervention data are preclinical. CPT has not entered clinical trials. Human evidence came from tissue and iPSC-derived neuron models, not treated patients. Two authors disclosed a company founding and advisory relationship.